BICO has completed the divestment of the Berlin property for a total of EUR 21m
November 30, 2023 5:45 pmBICO has, as of today, completed the divestment of the property in Berlin, Germany to BEOS. The transaction was communicated upon signing in August 2023 and BICO has now received the funds.
Closing of the transaction was subject to approval from the city of Berlin, which was granted in November 2023. The total sales price amounted to EUR 21m (approximately SEK 246m), and the sales price was 10% higher than book value. The transaction generates a positive cash flow contribution in Q4 2023.
As communicated in August, the transaction also includes a leaseback, with BICO company SCIENION as tenant where a long-term lease over 15 years with a break option after 10 years.
For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com
The information was submitted for publication, through the agency of the contact person set out above, on November 30, 2023 at 5.45pm CET.
About BICO
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.
The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.
With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 11,000 publications.
Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.
BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com